We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Contraceptive Patch Should Stay, But With Stronger Labeling, REMS
Contraceptive Patch Should Stay, But With Stronger Labeling, REMS
December 16, 2011
A joint FDA advisory panel is recommending Janssen Pharmaceuticals’ Ortho Evra transdermal contraceptive patch remain on the market as its benefits outweigh the risk of blood clots for most women.